Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

MLA

Noonan, Anne M., et al. “Pharmacodynamic Markers and Clinical Results from the Phase 2 Study of the SMAC Mimetic Birinapant in Women with Relapsed Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.” Cancer, vol. 122, no. 4, Feb. 2016, pp. 588–97. EBSCOhost, https://doi.org/10.1002/cncr.29783.

APA

Noonan, A. M., Bunch, K. P., Chen, J.-Q., Herrmann, M. A., Lee, J.-M., Kohn, E. C., O’Sullivan, C. C., Jordan, E., Houston, N., Takebe, N., Kinders, R. J., Cao, L., Peer, C. J., Figg, W. D., & Annunziata, C. M. (2016). Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer, 122(4), 588–597. https://doi.org/10.1002/cncr.29783

Chicago

Noonan, Anne M, Kristen P Bunch, Jin-Qiu Chen, Michelle A Herrmann, Jung-Min Lee, Elise C Kohn, Ciara C O’Sullivan, et al. 2016. “Pharmacodynamic Markers and Clinical Results from the Phase 2 Study of the SMAC Mimetic Birinapant in Women with Relapsed Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.” Cancer 122 (4): 588–97. doi:10.1002/cncr.29783.